Vaxart (VXRT) Stock News

Vaxart (NASDAQ: VXRT) has announced the adjournment of its 2025 annual stockholders meeting to June 13, 2025, at 8:30 a.m. PT. The adjournment affects all proposals outlined in the company's April 10 proxy statement. CEO Steven Lo reported positive discussions with major stockholders regarding the reverse stock split proposal (Proposal No. 2), with many indicating support following clarification of its importance for maintaining Nasdaq listing. Leading proxy advisory firms ISS and Glass Lewis have recommended stockholder support for the proposal. Stockholders of record as of March 26, 2025, can vote until June 12, 2025, at 11:59 p.m. ET. The reconvened meeting will be held virtually, accessible via the company's virtual shareholder meeting platform.

Vaxart (NASDAQ: VXRT), a clinical-stage biotech company specializing in oral recombinant pill vaccines, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management team will engage in a fireside chat on June 5, 2025, at 2:00 PM ET. The event will be accessible via live webcast on Vaxart's website, with a replay available for 30 days after the event. Investors seeking meetings with management during the conference should contact their Jefferies representative.

Vaxart (NASDAQ: VXRT) has released a video update from Founder and CSO Dr. Sean Tucker, urging stockholders to vote in favor of Proposal No. 2 for a reverse stock split. The proposal aims to help Vaxart regain compliance with Nasdaq's minimum bid price requirement. Stockholders of record as of March 26, 2025, must cast their votes by 11:59 p.m. Eastern Time on June 1, 2025. The company has also provided a fact sheet addressing common misconceptions about the reverse split proposal. Shareholders who previously voted against the proposal can change their vote, and assistance is available through Campaign Management, LLC.

Vaxart (VXRT) has provided detailed responses to stockholder questions ahead of its June 2, 2025 Annual Meeting, focusing on the crucial reverse stock split proposal. The company faces a June 30, 2025 Nasdaq compliance deadline and needs stockholder approval to maintain its listing. Key points include: the Board's commitment to a maximum 1-for-20 reverse split ratio (reduced from 1-for-50), plans to proportionally reduce authorized shares, and clarification on the $460.7 million BARDA Project NextGen award structure. The company has extended voting until June 1, 2025 at 11:59 p.m. ET. Management addressed concerns about dilution, short selling, and communication transparency, while emphasizing that the reverse split is currently the primary strategy for maintaining Nasdaq listing.

Vaxart (NASDAQ: VXRT) has initiated dosing in the 10,000-participant portion of its Phase 2b clinical trial for its oral pill COVID-19 vaccine candidate. The study will compare the efficacy, safety, and immunogenicity of Vaxart's oral vaccine against an approved mRNA COVID-19 vaccine in previously vaccinated adults. This advancement follows a positive 30-day safety review by an independent Data Safety Monitoring Board (DSMB) from the initial 400-participant sentinel cohort. The trial is funded through Project NextGen, with Vaxart receiving up to $460.7 million from BARDA and NIAID. The double-blind, multi-center, randomized, comparator-controlled study represents a significant milestone in developing an alternative to injectable COVID-19 vaccines.

Vaxart (NASDAQ: VXRT) has announced the adjournment of its 2025 annual stockholders meeting to June 2, 2025 at 8:30 a.m. Pacific Time. The virtual meeting will address all proposals from the proxy statement filed on April 10, 2025. The company is particularly focused on gaining stockholder approval for Proposal No. 2 regarding a Reverse Stock Split, which aims to regain Nasdaq compliance for minimum bid price requirements. The Board argues this split would help maintain Nasdaq listing, increase broker/analyst coverage, attract institutional investors, and aid in employee retention. Stockholders of record as of March 26, 2025, can vote until June 1, 2025 at 11:59 p.m. Eastern Time.

Vaxart (NASDAQ: VXRT) announced equity inducement awards for its new Chief Financial Officer, Jeroen Grasman, effective May 19, 2025. The compensation package includes: (1) an option to purchase 1,000,000 shares of common stock, vesting 25% after one year and 1/48th monthly thereafter, with exercise price at grant date closing price, and (2) a restricted stock unit (RSU) award of 350,000 shares, vesting 25% annually over four years. The awards were granted under Vaxart's 2024 Inducement Award Plan, complying with Nasdaq Listing Rule 5635(c)(4) for new employee inducement awards.

Vaxart (VXRT) has announced important amendments to its proxy statement for the upcoming Annual Meeting. The board has approved two key changes contingent on the passage of Proposal #2: limiting the reverse stock split ratio to no more than 1-for-20 and proposing to proportionally reduce the authorized number of common stock shares at a future special stockholder meeting. These changes come as Vaxart faces potential Nasdaq delisting and seeks stockholder approval for the reverse split to maintain its listing status. Leading proxy advisory firms ISS and Glass Lewis support Proposal #2. The company emphasizes that maintaining Nasdaq listing is crucial for stockholder liquidity and institutional investment accessibility. Stockholders can vote on Proposal #2 until May 20, 2025, at 11:59 p.m. ET, with previously cast negative votes eligible for change.

Vaxart (NASDAQ: VXRT) has received BARDA approval to begin dosing in the 10,000-participant portion of its Phase 2b clinical trial for its oral pill COVID-19 vaccine candidate. The double-blind, multi-center study will compare the efficacy, safety, and immunogenicity of Vaxart's oral vaccine to an approved mRNA COVID-19 vaccine in previously vaccinated adults.

The company expects to dose the first patient in Q2 2025. The trial is funded through Project NextGen, a $5 billion BARDA and NIAID initiative, with Vaxart's project award valued at up to $460.7 million through the Rapid Response Partnership Vehicle (RRPV) Consortium.